Cargando…
P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.
Autores principales: | Lasica, M., Spencer, A., Campbell, P., Wallington-Gates, C., Wong Doo, N., Janowski, W., McCaughan, G., Puliyayil, A., Yuen, F., Le, K., Reynolds, J., Quach, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430338/ http://dx.doi.org/10.1097/01.HS9.0000846652.51254.ac |
Ejemplares similares
-
The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma
por: McCurdy, Arleigh, et al.
Publicado: (2022) -
Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin
por: Lu, Rebecca, et al.
Publicado: (2023) -
The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020) -
Belantamab mafodotin associated corneal microcyst-like epithelial changes
por: Chuang, Katherine, et al.
Publicado: (2022) -
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety
por: Offidani, Massimo, et al.
Publicado: (2021)